← Human Trials & Peer-Reviewed Studies
Calcitonin as an Additive to Local Anesthetic and Steroid Injection Using a Modified Coronoid Approach in Trigeminal Neuralgia
Plain-language guide to PMID 27676662 (2016): double-blind randomized controlled trial study of Calcitonin, trigeminal neuralgia.
Key Facts
- PMID
- 27676662
- Journal
- Pain physician
- Year
- 2016
- Study type
- Randomized Controlled Trial
- Authors
- Elsheikh NA et al. (2 authors)
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Calcitonin in the context of trigeminal neuralgia.
The present study aimed to evaluate the effect of adding calcitonin to local anesthetic and methylprednisolone using a modified coronoid approach in management of trigeminal neuralgia pain involving the mandibular and/or maxillary branches.
Why It Was Studied
However, many patients become refractory to drugs.
Calcitonine, modifed, coronoid approach, trigeminal neuralgia.
Who Took Part
Thirty-three patients received maxillary and mandibular blocks by a modified coronoid approach.
Patients were allocated into 2 groups.
How the Study Was Run
The design is described as randomized and double-blind.
The participants were allocated by chance, so the Calcitonin group and the comparison group should start out alike.
Blinding on both sides kept the participants and researchers unaware of who received Calcitonin.
A time span of one year appears in the methods.
Randomized double blind clinical trial.
Pain was evaluated by visual analog scale (VAS) before the block (basal), at 2 weeks, one month after the procedure, and monthly for one year.
Repeated blockade was allowed for any patient reporting a VAS > 30 mm during one year of follow-up and the number of blocks were reported.
Adverse effects were also reported.
What Was Measured
PubMed files the paper under topics including Anesthesia, Local, Anesthetics, Local, Calcitonin, Pain Measurement and Trigeminal Neuralgia.
What This Means in Plain Language
The paper is a randomized and double-blind study of Calcitonin in people with trigeminal neuralgia over one year.
Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2016 (Pain physician), a journal based in United States.
More context: the Calcitonin compound page, Trigeminal neuralgia research.
Our Notes on the Compound
Calcitonin: A 32-amino-acid hormone that lowers blood calcium; salmon calcitonin (Miacalcin) has been used for Paget disease and osteoporosis.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.